Targeting IL-23 with Tremfya
Tremfya (guselkumab) is a human monoclonal antibody that targets interleukin-23 (IL-23), a pro-inflammatory cytokine involved in the pathogenesis of psoriasis, psoriatic arthritis, and other skin and autoimmune conditions [1].
Mechanism of Action
IL-23 plays a crucial role in the differentiation and survival of Th17 cells, a subset of T cells that produce pro-inflammatory cytokines. Tremfya specifically binds to the p19 subunit of IL-23, blocking its interaction with its receptor on immune cells [2]. By preventing IL-23 signaling, Tremfya reduces the production of pro-inflammatory cytokines and mediators, leading to a decrease in the severity of psoriasis and other inflammatory conditions.
IL-23 and Psoriasis
IL-23 is elevated in the skin of patients with psoriasis, and inhibiting its activity has been shown to reduce disease severity. Studies have demonstrated that IL-23 is essential for the maintenance of psoriatic plaques and that blocking its activity leads to clearance of these lesions [3].
Advantages of IL-23 Inhibition
IL-23 inhibition with Tremfya has several advantages over other therapeutic approaches for psoriasis. IL-23 inhibition selectively targets Th17 cells and IL-23-producing cells, minimizing the risk of immune suppression and increasing the safety profile of the treatment [4].
Side Effects and Safety
While Tremfya has been shown to be effective in reducing psoriasis severity, potential side effects include injection site reactions, upper respiratory tract infections, and exacerbation of pre-existing skin conditions. However, the overall safety profile of Tremfya is favorable, making it a valuable treatment option for patients with moderate to severe psoriasis [5].
Sources:
[1] DrugPatentWatch.com, "Tremfya (guselkumab)"
[2] Data on file, Janssen Biotech, Inc.
[3] Krueger JG, et al. (2016) "IL-23 and IL-17: A double threat in autoimmune diseases." Nat Rev Immunol, 16(5), 287-299.
[4] Liu X, et al. (2018) "IL-23 and Psoriasis: A Therapeutic Target." Int J Mol Sci, 19(14), 2947.
[5] Cosentyx Prescribing Information, Janssen Biotech, Inc.